AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4

Ignalis-M 50/500 Tablet ER

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Ignalis-M 50/500 Tablet ER

Diabex-Duo 50/500 Extended-Release tablets combine two medications to manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps prevent serious diabetic complications like nephropathy and vision loss, and may lessen the risk of cardiovascular events. Diabex-Duo 50/500 ER can be used alone or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is personalized based on your health status, blood sugar readings, and other medications. Consuming it with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes effectiveness; discontinuation should only occur under your physician's guidance. Adherence to your prescribed diet and exercise plan is crucial for diabetes control, as lifestyle factors significantly influence blood sugar regulation. Common side effects include nausea, vomiting, diarrhea, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, especially when used with insulin or sulfonylureas; learn to recognize and manage this complication. This medication isn't suitable for everyone. Inform your doctor of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption before starting treatment. Pregnant or lactating individuals require medical consultation. Interactions with other medications are possible; disclose all current medications to ensure safety. Alcohol should be limited due to its hypoglycemic effect. Your doctor will monitor kidney function and blood glucose levels throughout your treatment.

Uses of Ignalis-M 50/500 Tablet ER

Managing type 2 diabetes

Major Benefits of Ignalis-M 50/500 Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the entire tablet without chewing, crushing, or fracturing it. The Ignalis-M 50/500 Extended-Release tablet should be administered with food.

Common Side effects of Ignalis-M 50/500 Tablet ER:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Ignalis-M 50/500 Tablet ER:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the entire tablet; do not chew, crush, or fracture it. The Ignalis-M 50/500 Extended-Release tablet should be taken with a meal.

How Ignalis-M 50/500 Tablet ER works:

Ignalis-M 50/500 Extended-Release tablets combine sitagliptin and metformin to manage blood glucose levels. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and decreases hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and boosts insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent alcohol use with Ignalis-M 50/500 Extended-Release tablets is contraindicated.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Ignalis-M 50/500 tablets might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ignalis-M 50/500 tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.

KidneyKidneyCAUTION

Patients with kidney impairment should use Ignalis-M 50/500 Tablet ER cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates its use. Physician consultation is essential. Regular kidney function monitoring is recommended during treatment.

LiverLiverUNSAFE

Extended-release Ignalis-M 50/500 tablets are contraindicated for individuals with hepatic impairment and should be omitted. Medical advice is recommended.

What if you forget to take Ignalis-M 50/500 Tablet ER :

Should you forget to take your Ignalis-M 50/500 Tablet ER, ingest it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual regimen. Avoid taking a double dose.

Facts to Know About Ignalis-M 50/500 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Ignalis-M 50/500 Tablet ER

Ignalis-M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged use of Ignalis-M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, neurological issues such as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Ignalis-M 50/500 Tablet ER may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/500 Tablet ER components or excipients, or with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a potential side effect of Ignalis-M 50/500 Tablet ER. This is due to a buildup of lactic acid in the blood and is rare, but avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Ignalis-M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Ignalis-M 50/500 Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency (also known as MALA, or Metformin-associated lactic acidosis), is a potential side effect of Ignalis-M 50/500 Tablet ER. This occurs due to excessive lactic acid buildup in the blood and is rare, but avoided in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged use of Ignalis-M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container as directed on the label or packaging. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Ignalis-M 50/500 ER tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Ignalis-M 50/500 Tablet ER may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Ignalis-M 50/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Ignalis-M 50/500 Tablet ER with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA), is a potential side effect of Ignalis-M 50/500 Tablet ER. This rare complication is more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol, hence its avoidance in these groups. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Prolonged use of Ignalis-M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifested as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, supplemental vitamin B12 is recommended annually by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Ignalis-M 50/500 Tablet E...
94
MRP 109
13% off